Skip to main content
Clinical Trials/NCT06298981
NCT06298981
Recruiting
N/A

Pulse Rate and Breathing Rate Accuracy Study - NuraLogix AMC-SDK

Nuralogix Corporation1 site in 1 country60 target enrollmentFebruary 12, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pulse Rate and Breathing Rate
Sponsor
Nuralogix Corporation
Enrollment
60
Locations
1
Primary Endpoint
Breathing rate accuracy validation
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis.

Registry
clinicaltrials.gov
Start Date
February 12, 2024
End Date
June 30, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participants must have the ability to understand and provide written informed consent or have legally authorized representative consent to participate
  • Participant must be 18 to 81 years of age (≥ 18 age to \< 82)
  • Participant must be willing and able to comply with study procedures and duration
  • Participants or legally authorized representative must be able to read or write in English

Exclusion Criteria

  • Participants who refuse or are unable to provide to sign an informed written consent for study
  • Participants evaluated by the Investigator and Clinical Staff and found to be medically - unsuitable or have self-reported health conditions that are currently unstable as identified in the Health Assessment Form and Health Screening
  • Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor Region of Interest (ROI) which would limit the ability to test ROI needed for the study. Tattoo in the optical path which would limit the ability to test ROI needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the particular areas utilized.)
  • Participants with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, or other medical sensors (self- reported)
  • Other known health condition, should be considered upon disclosure in health assessment form

Outcomes

Primary Outcomes

Breathing rate accuracy validation

Time Frame: 1-2 hours

The purpose of this study is to conduct a Breathing Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) by manually scoring the collected waveform for data analysis

Pulse rate accuracy validation

Time Frame: 1-2 hours

This study will also assess the pulse rate measurements of the NuraLogix AMC-SDK for comparison to a standard ECG (GE Datex-Ohmeda) derived heart rate reference.

Secondary Outcomes

  • Pulse rate simulation(1-2 hours)

Study Sites (1)

Loading locations...

Similar Trials